Ribociclib (CAS: 1211441-98-3)
|
SKU-Pack Size | Availability | Size | Price | |
EBC51227-1ML | In Stock | 1mL(10mM in DMSO) | $118.50 | |
EBC51227-2MG | In Stock | 2mg | $58.50 | |
EBC51227-5MG | In Stock | 5mg | $118.50 | |
EBC51227-10MG | In Stock | 10mg | $148.50 | |
EBC51227-50MG | In Stock | 50mg | $328.50 |
Please Select The Country You Are In To Find Your Local Distributor. |
![]() |
EbioCell | Phone:(540) 808-3925 |
Imperial Business Park 4819 Emperor Boulevard, | E-mail:order@ebiocell.com | |
Canada | Suite 408 Durham, NC 27703, USA | Web:www.ebiocell.com |
Product Information | |||||||||||||||||||||
Synonym(s) | LEE011; LEE-011; LEE 011; Ribociclib | ||||||||||||||||||||
Chemical Name | 7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide | ||||||||||||||||||||
Application | LEE011 (NVP-LEE011) is a highly specific inhibitor of CDK4/CDK6 and functions via decreasing in phosphorylated RB and FOXM1. | ||||||||||||||||||||
CAS Number | 1211441-98-3 | ||||||||||||||||||||
Purity | ≥99.0% | ||||||||||||||||||||
Molecular Weight | 434.54 | ||||||||||||||||||||
Molecular Formula | C23H30N8O | ||||||||||||||||||||
SMILES | CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5 | ||||||||||||||||||||
Target & IC50 | CDK4: IC50=10 nM CDK6: IC50=39 nM |
||||||||||||||||||||
Solubility | DMSO: 10.88mg/mL | ||||||||||||||||||||
Preparing Stock Solutions |
|
||||||||||||||||||||
Shipping | Gel Pack | ||||||||||||||||||||
Storage | Store at -20°C | ||||||||||||||||||||
Research Use | For Research Use Only. Not Intended for Diagnostic Or Therapeutic Use. |
Product Description | |
LEE011 (NVP-LEE011) is a highly specific inhibitor of CDK4/CDK6 and functions via decreasing in phosphorylated RB and FOXM1. When tested with 17 human neuroblastoma cell lines, 12 of them were sensitive to LEE011 treatment with mean IC50=306±68 nM. CDK4/6 could increase G1-S phase cell cycle progression and ultimately cellular proliferation via phosphorylating tumor suppressor protein RB. CDK4/6 signaling also could senescence suppression by regulating FOXM1 transcription. Numerous studies have shown that over-expression of CDK4/CDK6 correlated with tumorigenesis and disease progression. |
Specific Protocols | |